Literature DB >> 15808954

Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate.

David Danielpour1.   

Abstract

The prostate is a highly androgen-dependent tissue that in humans exhibits marked susceptibility to carcinogenesis. The malignant epithelium generated from this tissue ultimately loses dependence on androgens despite retention or amplification of the androgen receptor. Accumulating evidence support that transforming growth factor-beta (TGF-beta) plays key roles in the control of androgen dependence and acquisition of resistance to such hormonal control. Although TGF-beta functions as a key tumour suppressor of the prostate, it can also promote malignant progression and metastasis of the advanced disease, through undefined mechanisms. In addition to giving an overview of the TGF-beta field as related to its function in prostate cancer, this Review focuses on novel findings that support the tumour suppressor function of TGF-beta is lost or altered by changes in the activity of the androgen receptor, insulin-like growth factor-I, Akt, and mTOR during malignant progression. Understanding the mechanisms of cross-talk between TGF-beta and such growth modulators has important implications for the rational therapeutics of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808954     DOI: 10.1016/j.ejca.2004.12.027

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  41 in total

1.  Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; David Danielpour
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

2.  Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.

Authors:  Mitchell G Lawrence; Naira V Margaryan; Daniela Loessner; Angus Collins; Kris M Kerr; Megan Turner; Elisabeth A Seftor; Carson R Stephens; John Lai; Lynne-Marie Postovit; Judith A Clements; Mary J C Hendrix
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

3.  Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

Authors:  Mingfang Ao; Karin Williams; Neil A Bhowmick; Simon W Hayward
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

Review 4.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.

Authors:  Jorge A Garcia; David Danielpour
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

5.  Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.

Authors:  Likun Li; Chengzhen Ren; Guang Yang; Alexei A Goltsov; Ken-ichi Tabata; Timothy C Thompson
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

6.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

7.  Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.

Authors:  Katayoon H Emami; Lisha G Brown; Tiffany E M Pitts; Xizhang Sun; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

8.  Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Seong-Jin Kim; David Danielpour
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells.

Authors:  Jiayi Yang; Reema Wahdan-Alaswad; David Danielpour
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 10.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.